Lecithins Patents (Class 514/78)
  • Patent number: 10259834
    Abstract: Racemic or optically active D- or L-?-glycerophosphoryl choline solids are prepared from liquid type racemic or optically active D- or L-?-glycerophosphoryl choline using an organic solvent. The solids are produced at a high yield more easily through phase transformation than an existing method using a difference in solubility in a solvent.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: April 16, 2019
    Assignee: ENZYTECH, LTD.
    Inventors: Soon Ook Hwang, Dae Myoung Yun, Chang-min Kim
  • Patent number: 10117883
    Abstract: This invention relates to compositions containing combinations of a balanced phosphatidylcholine composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of using such combinations to treat subjects suffering from an imbalance of fatty acids and related diseases or disorders. This invention also relates to the synergistic effect of such combination therapies in humans.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: November 6, 2018
    Assignee: BODYBIO INC.
    Inventors: Edward Kane, Patricia Kane, Brett T. Hauser
  • Patent number: 9968622
    Abstract: Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids, are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4?-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201).
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: May 15, 2018
    Assignee: Vascular Biogenics Ltd.
    Inventors: Gideon Halperin, Eti Kovalevski-Ishai
  • Patent number: 9603811
    Abstract: The present invention provides pharmaceutical compositions comprising a chylomicron and a carotenoid. The present invention also provides pharmaceutical compositions comprising a micelle and a carotenoid, suspended in an aqueous solution and suitable for intravenous administration. The bioavailability of the carotenoid of the pharmaceutical composition is higher relative to the bioavailability of free carotenoid.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: March 28, 2017
    Assignee: Health-Ever Biotech Co., Ltd
    Inventors: Fu Feng Kuo, Bin-huei Chen
  • Patent number: 9474765
    Abstract: A composition for inducing lipolysis includes phosphatidylcholine and a preparation method therefor. More particularly, the composition for inducing lipolysis may include 2-12% (w/v) of phosphatidylcholine, 5-12% (w/v) of an oily solvent, and a balance of water; and a preparation method thereof. The composition may include phosphatidylcholine, an oily solvent, and water to induce lipolysis without causing such adverse side effects as edema, erythema, tissue necrosis, and inflammation.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: October 25, 2016
    Assignee: AMI Pharm Co., Ltd.
    Inventor: Ki Teak Lee
  • Patent number: 9458409
    Abstract: The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: October 4, 2016
    Assignee: Arctic Nutrition AS
    Inventors: Hogne Hallaraker, Jan Remmereit, Alvin Berger
  • Patent number: 9408857
    Abstract: Methods relating to local injections of corticosteroids are provided. More specifically intralesional injections of corticosteroids and preferably Triamcinolone and its derivatives are suitable to produce medicaments to be injected in the subcutaneous fat at deep levels to provoke cosmetic lipoatrophy of small fat deposits on the face and body.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: August 9, 2016
    Inventor: Doris Hexsel
  • Patent number: 9399042
    Abstract: The invention described herein relates to the use of an aqueous composition containing at least one phospholipid. at least one glycyrrhizic acid or salts of glycyrrhizic acid for the manufacture of mediciments for the removal of subcutaneous fat accumulation.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: July 26, 2016
    Assignee: Lichtblick GmbH
    Inventors: Karl-Josef Gundermann, Dirk Brandl
  • Patent number: 9364461
    Abstract: The present invention relates to new processes for the preparation of oil-in-water emulsions useful in ophthalmic applications. In particular, processes are provided that include preparing a pre-concentrate of the oil-in-water emulsion, and diluting the pre-concentrate obtained to form the desired oil-in-water emulsion. The present invention also provides pharmaceutical compositions comprising an oil-in-water emulsion prepared by an inventive process, and methods of using these compositions for the treatment of an eye disease or condition.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: June 14, 2016
    Assignee: SANTEN SAS
    Inventors: Gregory Lambert, Frederic Lallemand, Laura Rabinovich-Guilatt, Pascal Candillon, Julien Lafosse
  • Patent number: 9192674
    Abstract: The present disclosure is directed generally to cosmetic compositions comprising EPA free acid and GLA free acid. In some embodiments, the cosmetic compositions have a cosmetically acceptable odor.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: November 24, 2015
    Assignee: Dignity Sciences Limited
    Inventors: Mehar Manku, John Climax, David Coughlan
  • Patent number: 9137991
    Abstract: This invention pertains to a choline containing composition, delivered through a delivery system, to reverse the negative effects of urine on plants, containing turf grass, ornamental flowers, shrubs and bushes. The invention also provides method to deliver choline containing products to the foliar portion of plants.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: September 22, 2015
    Assignee: Floratine Products Group, Inc.
    Inventors: Kevin Cavanaugh, Timothy B Cartwright
  • Patent number: 9132109
    Abstract: A method for treating non-asthmatic bronchitis with a particular lysine acetylsalicylate is described. The lysine acetylsalicylate is delivered by nebulizer, preferably, to treat acute bronchitis, chronic bronchitis, emphysema and chronic obstructive pulmonary disease.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: September 15, 2015
    Assignee: MEDESTEA RESEARCH & PRODUCTION S.P.A.
    Inventors: Jose Sebastian Franzone, Sebastiano Bianco, Giuseppe Zuccari, Claudio Franco Omini
  • Patent number: 9101637
    Abstract: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: August 11, 2015
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Lenard M. Lichtenberger
  • Patent number: 9023833
    Abstract: The invention relates to a method for treating sepsis in subjects who exhibit serum albumin levels, and one of total cholesterol or HDL levels, above minimum threshold values. The method involves intravenous administration of an emulsion, which contains a phospholipid, a neutral lipid, and a cholate salt.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: May 5, 2015
    Assignee: Sepsicure, LLC
    Inventors: Daniel M. Levine, Thomas S. Parker, Bruce R. Gordon, Stuart D. Saal
  • Publication number: 20150104503
    Abstract: A complex is provided, including a phospholipid and curcumin, wherein the phospholipid is sourced from a marine oil.
    Type: Application
    Filed: May 22, 2013
    Publication date: April 16, 2015
    Inventor: Harold Gordon CAVE
  • Patent number: 9006217
    Abstract: Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids, are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4?-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: April 14, 2015
    Assignee: Vascular Biogenics Ltd.
    Inventors: Gideon Halperin, Eti Kovalevski-Ishai
  • Patent number: 9000013
    Abstract: The present invention discloses methods of application employing B51B6 vitamins in molecular transport creams or gels to deliver B6 in a high dose to bring about therapeutic ways in human or mammal tissues to reverse a disease process or injury to bring about normal function of the affected tissues. Examples of disease changes to normal include, but are not limited to strokes, cellulitis, facial acne, precancerous lesions, nerve injury like paresthesia, periorbital hematoma, pentathol general anesthesia recovery, headaches, improved sight, hypothyroidism, dental pain, dental gingivitis, insect bites, delayed hypersensitivity states, phlebitis of veins and synergism of steroid activity.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: April 7, 2015
    Inventor: Alfred A. Nickel
  • Publication number: 20150065462
    Abstract: Conjugates of drugs suitable for use in the treatment of inflammatory bowel disease and phospholipids, and their use in the treatment of inflammatory bowel disease, are disclosed. The disclosed conjugates serve as targeted prodrugs which are suitable for oral administration, and which are capable of releasing the drug selectively at the diseased tissue upon activation by PLA2.
    Type: Application
    Filed: November 10, 2014
    Publication date: March 5, 2015
    Inventor: Arik DAHAN
  • Publication number: 20150011507
    Abstract: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration.
    Type: Application
    Filed: September 24, 2014
    Publication date: January 8, 2015
    Applicant: The Board of Regents of the University of Texas System
    Inventor: Lenard M. LICHTENBERGER
  • Publication number: 20140377364
    Abstract: A spray-chilled particulate delivery system that has a crystalline matrix structure and comprises a volatile hydrophobic active ingredient and a carrier material selected from the group consisting of erythritol and mannitol and mixtures thereof wherein, relative to the total weight of the carrier material, 75% or more of the carrier material is in crystalline form. The process for preparing the delivery system comprises the steps of (i) forming a melt of a carrier material selected from the group consisting of erythritol and mannitol and mixtures thereof (ii) incorporating a volatile hydrophobic active ingredient into the melt (iii) forming a melt-mixture comprising an emulsion, dispersion or suspension of the volatile hydrophobic active ingredient in the melt (iv) forming discrete particles of the melt mixture, and (v) cooling the discrete particles, so as to form the crystalline delivery system.
    Type: Application
    Filed: September 9, 2014
    Publication date: December 25, 2014
    Applicant: FIRMENICH SA
    Inventors: Christopher M. GREGSON, Matthew P. SILLICK
  • Patent number: 8911752
    Abstract: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulstion for internal, oral, direct or topical administration.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: December 16, 2014
    Assignee: The Board of Regents of the University of Texas System
    Inventor: Lenard M. Lichtenberger
  • Patent number: 8906886
    Abstract: A method of treating a subject and preventing in a subject age-dependent basal forebrain cholinergic dysfunction related neurodegenerative disorders, comprising: administering a lipid composition comprising a therapeutically effective amount of highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phospholipids to promote survival of aged basal forebrain cholinergic neurons, the phospholipids selected from the group consisting of phosphatidylserine, phosphatidylethanolamine, and phosphatidyl-monomethylethanolamine.
    Type: Grant
    Filed: July 3, 2009
    Date of Patent: December 9, 2014
    Inventors: Su Chen, Rainbow Chen
  • Patent number: 8877239
    Abstract: Nutritional supplement formulations suitable for specific enhancement of cell and mitochondrial function comprise enriched formulations of phospholipids and chemical precursors containing specifically identified concentrations of phosphatidylglycerol, phosphatidic acid and phosphatidylcholine, and mitochondrial and cell membrane phospholipid molecules as well as other desirable constituents. Methods of enriching extracted sources of cell and mitochondrial membrane molecules and precursors from microbes, plants and other sources are also set forth. The formulae can be combined with nutritional, prebiotic, and probiotic (microbial) factors that increase bioavailability through the digestive tract and increase absorption at the cellular and subcellular levels. These lipid combinations can be used to treat mitochondrial disorders associated with medical pathologies, chronic illnesses and syndromes, or to maintain lipid balance for normal mitochondrial function, and can be administered in many different forms.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: November 4, 2014
    Assignee: Nutritional Therapeutics, Inc.
    Inventors: Robert Settineri, James F. Palmer
  • Patent number: 8865187
    Abstract: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulstion for internal, oral, direct or topical administration.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: October 21, 2014
    Assignee: The Board of Regents of the University of Texas System
    Inventor: Lenard M. Lichtenberger
  • Patent number: 8865681
    Abstract: In one embodiment, the invention provides a method of treating, reducing the incidence, reducing the severity or pathogenesis of an eye disease or disorder in a subject, including, inter alia, retinal detachment, macular degeneration, glaucoma or retinopathy, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a contact lens solution comprising a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: October 21, 2014
    Assignee: Yissum Research Development Company of the Hebrew Unitersity of Jerusalem
    Inventors: Saul Yedgar, Yuval Cohen
  • Publication number: 20140308339
    Abstract: The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.
    Type: Application
    Filed: July 10, 2013
    Publication date: October 16, 2014
    Inventors: Robert O. RYAN, Michael N. ODA
  • Publication number: 20140287075
    Abstract: The present invention relates to a composition and a kit for the protection, treatment and repair of cartilage in humans and animal joints. The composition or kit contains a combination of unsaponifiable lipids together with one or more of polyphenols and/or catechins. Preferably, the composition or kit contains avocado:soybean unsaponifiables (ASU) and green tea.
    Type: Application
    Filed: June 4, 2014
    Publication date: September 25, 2014
    Inventors: Todd R. Henderson, Louis Lippiello, Charles Filburn, David Griffin
  • Publication number: 20140274875
    Abstract: Compositions and methods for achieving hemostasis. Hemostatic compositions comprise a phospholipid, and optionally, an anti-infective agent. The hemostatic composition can be administered to a bleeding bone to achieve hemostasis.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Inventors: Karen S. TROXEL, Michael PONTICIELLO
  • Publication number: 20140274957
    Abstract: The present invention includes compositions and methods for treating certain conditions, the composition comprising a choline compound; a cholinesterase inhibitor; and Acetyl-L-Carnitine, wherein the composition is used to treat at least one of autonomic dysfunctions or vascular diseases.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Inventor: Diana Driscoll
  • Patent number: 8822549
    Abstract: An oxygen therapeutic composition, comprising a perfluorocarbon material, a viscosity modifier, a buffer, wherein the buffer stabilizes a pH of the composition at between about 6.5 to about 7.5, and wherein the composition comprises a viscosity of about 2.0 to about 3.5 mPas, and wherein the fluorocarbon has a boiling point of about 4 degrees Celsius to about 60 degrees Celsius.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: September 2, 2014
    Inventors: Jennifer L. Johnson, Evan C. Unger
  • Patent number: 8802656
    Abstract: A new pharmaceutical composition is disclosed comprising a purified phospholipid-selective and/for nonselective non-steroidal, anti-inflammatory drug associated complex and methods for making and using same. A screening method for identifying compounds that form phospholipid associated complexes is also disclosed.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: August 12, 2014
    Assignee: The Board of Regents of the University of Texas System
    Inventor: Lenard Lichtenberger
  • Publication number: 20140193493
    Abstract: The present invention relates to solid dosage forms of oleyl phosphocholine (C18:1-PC), or OlPC, for oral administration. Further, the present invention relates to methods for the preparation of the present solid dosage forms and the use thereof as a medicament and especially a medicament for treatment of parasitic diseases, such as leishmaniasis, chagas and malaria, and cancer both in humans and animals. Specifically, the present invention relates to a solid dosage form comprising: 6 to 25 weight % of the solid dosage form oleyl phosphocholine; 20 to 35 weight % of the solid dosage form lactose; 35 to 50 weight % of the solid dosage form cellulose; 5 to 20 weight % of the solid dosage form croscarmellose; 1 to 10 weight % of the solid dosage form hydroxypropylmethyl cellulose; and 0.05 to 1 weight % of the solid dosage form of a lubricant.
    Type: Application
    Filed: November 21, 2011
    Publication date: July 10, 2014
    Applicant: DAFRA PHARMA RESEARCH & DEVELOPMENT BVBA
    Inventor: Bruno Jansen
  • Publication number: 20140171391
    Abstract: The invention relates to a method for treating sepsis in subjects who exhibit serum albumin levels, and one of total cholesterol or HDL levels, above minimum threshold values. The method involves intravenous administration of an emulsion, which contains a phospholipid, a neutral lipid, and a cholate salt.
    Type: Application
    Filed: December 18, 2012
    Publication date: June 19, 2014
    Applicant: THE ROGOSIN INSTITUTE
    Inventors: Daniel M. LEVINE, Thomas S. Parker, Bruce R. Gordon, Stuart D. Saal
  • Publication number: 20140155354
    Abstract: The present invention discloses processes for the preparation of phospholipid-enriched dairy products as nutraceuticals for the formulation of functional foods, and nutraceutical and/or pharmaceutical compositions thereof, the processes include the steps of: combining a non-dairy-based PL-containing material with an oil component and water to form a paste; removing an excess amount of the water from the paste to form a PL-oil solution; and mixing the PL-oil solution with a dairy component, thereby obtaining a PL-enriched dairy product. Preferably, the PL-containing material includes at least one material selected from the group consisting of: a vegetal-derived lecithin, a non-vegetal-derived lecithin, a de-oiled lecithin, a native lecithin-oil solution, and an enzymatically-processed lecithin. Preferably, the PL-oil solution has a weight-to-weight (w-w) concentration of at least about 0.01% of a residual amount of the water to the PL-containing material.
    Type: Application
    Filed: March 3, 2013
    Publication date: June 5, 2014
    Applicant: Lipogen Ltd.
    Inventors: David Rutenberg, Ilan Perry
  • Publication number: 20140141074
    Abstract: The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition.
    Type: Application
    Filed: October 15, 2013
    Publication date: May 22, 2014
    Applicant: Acasti Pharma, Inc.
    Inventors: Fotini Sampalis, Henri Harland
  • Patent number: 8722648
    Abstract: The inventions relates to a liquid pharmaceutical form containing an active ingredient alkylphosphocholines and a co-solvent system. The co-solvent system is mixture from hexylene glycol, propylene glycol, diethylene glycol monoethyl ether and water. The pharmaceutical form having a pH value in the range of 4 to 6, which if it is necessary can be achieved by adding a pH adjuster. The composition has a good storage stability and it is suitable for local application on the different organs of the body. The inventions relates also to a method for producing the same pharmaceutical form.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: May 13, 2014
    Inventor: Paul Meng
  • Publication number: 20140120181
    Abstract: The present invention relates to a new use of phosphatidylcholine, and more particularly to a composition for toxicity reduction of an anti-cancer agent, and an anti-cancer adjuvant, comprising phosphatidylcholine as an active ingredient.
    Type: Application
    Filed: December 24, 2013
    Publication date: May 1, 2014
    Inventors: Ki Teak LEE, Jong Hyuk LEE, Ji Hoon JEONG
  • Patent number: 8709449
    Abstract: The present invention provides methods and compositions for increasing the effectiveness of photodynamic therapy (“PDT”) and for reducing the duration of skin phototoxicity associated with PDT treatment. The disclosed methods generally include the administration of a lipid composition before, during, or after the administration of photosensitizers used in the PDT treatment protocol. The lipids are preferably phospholipids. It was discovered that the disclosed methods resulted in a more rapid clearance of photosensitizers from the skin and other tissue of patients, which results in a shorter period of skin phototoxicity after PDT treatment. The present invention also provides a composition which is preferably comprised of non-polar photosensitizers and phospholipids.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: April 29, 2014
    Assignee: Biolitec Pharma Marketing Ltd
    Inventors: Volker Albrecht, Susanna Gräfe
  • Patent number: 8703179
    Abstract: A mucosal formulation for administration to mucosal membranes, such as in the mouth, nasal passage, stomach, vagina, etc., is disclosed. The mucosal formulation contains a lipid-pharmaceutical agent complex formed from phospholipids possessing a hydrophobic moiety that orients into a hydrophobic phase and a polar head moiety that orients towards the aqueous phase (i.e., “amphipathic” lipids). When placed in an aqueous medium (e.g., vaginal fluid), the phospholipids form liposomes or other small lipid vesicles (e.g., micelles) that may then be used to deliver pharmaceutical agents into a living organism.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: April 22, 2014
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: RameshBabu Boga, Robert B. Johnson
  • Publication number: 20140107072
    Abstract: A new method for krill meal production has been developed using a two step cooking process. In the first step the proteins and phospholipids are removed from the krill and precipitated as a coagulum. In the second stage the krill without phospholipids are cooked. Following this, residual fat and astaxanthin are removed from the krill using mechanical separation methods. A novel krill meal product with superior nutritional and technical properties is prepared.
    Type: Application
    Filed: December 20, 2013
    Publication date: April 17, 2014
    Applicant: Aker BioMarine AS
    Inventors: Snorre Tilseth, Øistein Høstmark
  • Patent number: 8686029
    Abstract: Antioxidant compositions for the stabilization of fat sources against oxidation, stabilized fat source compositions, and methods of stabilizing fat sources against oxidation are described. In particular, an antioxidant emulsion that includes quercetin in addition to at least one other ingredient and a lipid carrier is described.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: April 1, 2014
    Assignee: Novus International, Inc.
    Inventors: Gary Reznik, David Michael T. Macaraeg
  • Patent number: 8673285
    Abstract: The present invention concerns the use of a sphingoid-polyalkylamine conjugate as a capturing agent of biologically active molecules, such as antigens. In a particular embodiment, the spinogid-polyalkylamines are used for the preparation of pharmaceutical composition for modulating the immune response of a subject. Other aspects of the invention concern methods for modulating the immune response of a subject by the use of the conjugate, complexes comprising, the sphingoid-polyalkylamine conjugate in combination with a biologically active molecule capable of modulating an immune response of a subject, compositions comprising the conjugate as well as kits making use of said conjugate. A preferred conjugate according to the invention is N palmitoyl D-erythro sphingosyl 1 carbamoyl spermine.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: March 18, 2014
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Biolab Ltd.
    Inventors: Yechezkel Barenholz, Aviva Joseph, Eliezer Kedar
  • Patent number: 8668937
    Abstract: The present invention generally relates to compositions and methods for transdermal drug delivery. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction, treating wounds, or causing or promoting hair growth. For example, in one aspect, the present invention is generally directed to compositions for delivery of nitric oxide, transdermally and/or to a mucosal surface. The composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances.
    Type: Grant
    Filed: March 17, 2012
    Date of Patent: March 11, 2014
    Assignee: Transdermal Biotechnology, Inc.
    Inventors: Nicholas V. Perricone, Yousry Abdelrehim Sayed
  • Publication number: 20140051663
    Abstract: The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations.
    Type: Application
    Filed: October 25, 2013
    Publication date: February 20, 2014
    Applicant: ENZYMOTEC LTD.
    Inventors: Gai Ben Dror, Dorit Platt, Orly Farkash, Rassan Zuabi, Zohar Bar-On, Avidor Shulman, Dori Pelled, Yael Richter
  • Patent number: 8642645
    Abstract: The present invention relates to a pharmaceutical composition comprising ?9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resvertrol, and combinations thereof, wherein the composition exhibits an increased but negated psychoactivity with concurrent enhancement in therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: February 4, 2014
    Assignee: Brooks Kelly Research, LLC.
    Inventor: Brooks J. Kelly
  • Patent number: 8637688
    Abstract: The present invention relates to pharmaceutical dosage forms for topical administration comprising a tri-substituted glycerol compound or a pharmaceutically acceptable salt thereof. The invention also relates to a corresponding method for preparing such dosage forms as well as to their use as medicaments for the treatment of cancer and immune diseases.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: January 28, 2014
    Inventors: Julia Diederichs, Wolfgang Richter, Lutz Weber
  • Publication number: 20140005144
    Abstract: It is an object of the present invention to provide a leukotriene receptor antagonist that can be conveniently prepared from a natural source. The object has been achieved by finding that a marine product such as a squid phospholipid extract or an Akiami paste shrimp phospholipid extract contains the antagonists of BLT and CysLT1, which are leukotriene receptors. Therefore, the present invention provides a dietary composition and a pharmaceutical composition for inhibiting the activity of leukotriene receptors, containing a squid phospholipid extract or an Akiami paste shrimp phospholipid extract.
    Type: Application
    Filed: August 28, 2013
    Publication date: January 2, 2014
    Applicant: BIZEN CHEMICAL CO., LTD.
    Inventors: Teruyuki Kanada, Toru Kuyama, Takahiko Hada, Takafumi Ishihara
  • Patent number: 8604005
    Abstract: The invention relates to the use of probiotics in the manufacture of a composition for enhancing a metabolic profile in a subject. The probiotics are capable of preventing and treating diseases or disorders associated with an abnormal metabolic profile, especially a lipid profile by normalizing the profile. The probiotics are particularly effective in down-regulating levels of lysophosphatiydylcholines (LysoPCs) and ceramides.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: December 10, 2013
    Assignee: Valio Ltd.
    Inventors: Kajsa Kajander, Riitta Korpela
  • Publication number: 20130316980
    Abstract: An aqueous composition for application in a method for surgical or therapeutic treatment of the human or animal body or in a diagnostic procedure which is practiced on the human or animal body, the composition comprising osmotically active particles and containing less than 70 ?l?1 of amniotic cells, the osmolarity of the composition being in the range from 240.0 mosm/l to less than 308.0 mosm/l, and the chloride ion concentration in the composition being not more than 130.0 mmol/l. An aqueous composition for application with an amniotic infusion, the composition containing less than 70 ?l?1 of amniotic cells and comprising at least one surfactant, is also disclosed.
    Type: Application
    Filed: January 4, 2012
    Publication date: November 28, 2013
    Inventor: Michael Tchirikov
  • Publication number: 20130310339
    Abstract: A sexual function improving agent and the use thereof. Said sexual function improving agent comprises a phospholipid including a highly unsaturated fatty acid as a constituent fatty acid.
    Type: Application
    Filed: February 1, 2012
    Publication date: November 21, 2013
    Applicant: NIPPON SUISAN KAISHA, LTD.
    Inventors: Li Han, Tomoko Tsuji, Pengtao Li, Jun Wang, Hongtao Lei